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Response to drug therapy in individual colorectal cancer (CRC) patients is associated with
tumour biology. Here we describe the genomic landscape of tumour samples of a
homogeneous well-annotated series of patients with metastatic CRC (mCRC) of two phase III
clinical trials, CAIRO and CAIRO2. DNA copy number aberrations of 349 patients are
determined. Within three treatment arms, 194 chromosomal subregions are associated with
progression-free survival (PFS; uncorrected single-test P-values o0.005). These subregions
are ﬁltered for effect on messenger RNA expression, using an independent data set from The
Cancer Genome Atlas which returned 171 genes. Three chromosomal regions are associated
with a signiﬁcant difference in PFS between treatment arms with or without irinotecan. One
of these regions, 6q16.1–q21, correlates in vitro with sensitivity to SN-38, the active metabolite
of irinotecan. This genomic landscape of mCRC reveals a number of DNA copy number
aberrations associated with response to drug therapy.
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C
olorectal cancer (CRC) is the second leading cause of
cancer death in the western world with 1.2 million new
cases and over 600,000 deaths worldwide in 2008 (ref. 1).
CRC results from the accumulation of multiple genetic and
epigenetic aberrations2, in which patterns are not homogeneous.
Based on the paradigm that genotype drives phenotype, in cancer
as well as in evolution, inter tumour heterogeneity is thought to
be associated to differences in clinical outcome in CRC, in
particular to response to systemic treatment. A classic example is
failure of anti-epidermal growth factor receptor (EGFR) therapy
in RAS mutated metastatic CRC (mCRC)3. However, current
systemic treatment for mCRC is still largely based on shot gun
approaches (‘one-size-ﬁts-all’), and most patients are treated
empirically with ﬂuoropyrimidine-based chemotherapy regimens
with or without oxaliplatin or irinotecan and bevacizumab, while
the EGFR-targeted monoclonal antibodies cetuximab and
panitumumab are administered to patients with RAS wild-type
tumours. To avoid unnecessary toxicity, improve individual
patient’s outcomes and constrain healthcare costs, biomarkers
predictive of response are needed4,5. The principle of predictive
biomarkers is based on matching the right combination of drugs
with particular biological subclasses of CRC.
The biology underlying CRC phenotypes, including response
to drug therapy, can be read out at the DNA, RNA and protein
level. At this point in time, DNA copy number proﬁling is the one
method that both offers genome-wide coverage and works
reliably with formalin-ﬁxed parafﬁn-embedded (FFPE) tissue
samples, which is commonly available, both for use in clinical
trials investigating novel (combination) treatment for metastatic
disease as well as in routine clinical practice. Moreover, DNA
copy number proﬁling is important to understand the biology of
CRC in individual patients, a stepping stone to personalized
treatment. For example, DNA copy number aberrations have
been found to be predictors of response to the targeted agents
trastuzumab, lapatinib and to anthracyclins in breast cancer6–8 as
well as to carboplatin in ovarian cancer and irinotecan in
CRC9,10. However, apart from HER2 ampliﬁcation for
trastuzumab, clinical validation of these candidate predictive
biomarkers is lacking.
In the present study we aim to document the landscape of
DNA copy number aberrations in primary tumours of the deﬁned
subset of CRC patients who developed metastatic disease and are
amenable for systemic treatment. Recent advances in genome
technologies have resulted in several series of CRC samples that
have been systematically analyzed for genetic aberrations11–16. In
addition to powerful genomics, homogeneity of phenotypes is
also important to derive strong genotype–phenotype associations,
which has been a limitation in some series. Samples included in
the present study were restricted to those obtained from patients
who participated in one of two phase III clinical trials in mCRC,
either studying sequential versus combination chemotherapy with
capecitabine, irinotecan and oxaliplatin (CAIRO (ref. 17)) or
capecitabine, oxaliplatin and bevacizumab with or without
cetuximab (CAIRO2 (ref. 18)); nota bene cetuximab-treated
patients were omitted in the present study given an inferior
progression-free survival (PFS) observed with this regimen.
Such data are hypothesis generating in terms of potential
biomarkers for prediction of response to the respective drug
regimens the patients have been treated with. Moreover it can
serve as a catalogue of related ampliﬁcations of loci carrying genes
against the products of which already drugs exist and have been
approved for use. To this end, a large high-quality array
comparative genomic hybridization (aCGH) data set of clinically
well-annotated CRC specimens was generated using FFPE
tumour samples from patients who participated in two phase
III clinical trials (CAIRO (ref. 17) and CAIRO2 (ref. 18)).
Results
Final data set and descriptives. After passing all our inclusion
criteria the ﬁnal data set comprised 349 high-quality copy
number proﬁles of 105, 111 and 133 samples of the patient
groups; CAIRO arm-A ﬁrst-line capecitabine (CAP), CAIRO
arm-B ﬁrst-line capecitabine plus irinotecan (CAPIRI) and
CAIRO2 arm-A ﬁrst-line treatment with capecitabine, oxaliplatin
and bevacizumab (CAPOX-B), respectively (Fig. 1).
Quality of the obtained DNA copy number proﬁles was high,
both when measured by the median absolute deviation (MAD)
quality measure (average 0.17 and s.d. 0.05, range 0.09–0.39) and by
visual inspection, shown for three cases in Supplementary Fig. 1.
Overall, the frequency distribution of DNA copy number
aberrations was similar for all three arms (Fig. 2) and compared
with what has been reported previously for CRC14,19,20, with most
common gains at chromosomes 7, 8q, 13 and 20 and most common
losses at 1p, 4, 8p, 14, 15, 17p and 18. Patient characteristics of the
349 CAIRO and CAIRO2 samples included in the study
corresponded well to those of the overall trial population
(Supplementary Table 1), implicating that a representative group
of patients was proﬁled. Also the median PFS in the three arms was
comparable to PFS in the original studies as a whole
(Supplementary Fig. 2) if corrected for patients who underwent
resection of the primary tumour. As expected, PFS of the ﬁrst-line
therapy between the three arms differed signiﬁcantly
(Supplementary Fig. 2, P-values were 0.0018, o0.001 and 0.004
for CAP versus CAPIRI, CAP versus CAPOX-B and CAPIRI versus
CAPOX-B, respectively). This is explained by the different
treatment regimens in each study arm, as well as by differences
in patient inclusion criteria between CAIRO and CAIRO2.
Unsupervised analysis of DNA variation. In a ﬁrst attempt to
evaluate the association of genome variation in mCRC to
response to ﬁrst-line systemic treatment, we performed an
unsupervised hierarchical cluster analysis including all 349 CRC
samples. Unsupervised hierarchical cluster analysis revealed two
distinct clusters of 252 and 97 cases, respectively (Supplementary
Fig. 3). The n¼ 97 cluster contained CRCs with relatively few
copy number aberrations. This ‘silent cluster’ also contained the
majority of MSI tumours (n¼ 19 out of 21, P-value w2o0.001).
However, for none of the three regimens, an association of cluster
membership with PFS was found (log-rank P-value¼ 0.6, 0.3, 0.5
for CAP, CAPIRI and CAPOX-B, respectively). Even a more
detailed subdivision into three clusters (of n¼ 77, 175 and 97,
respectively) revealed no association (P-values are 0.4, 0.2 and 0.3
for CAP, CAPIRI and CAPOX-B, respectively). Since the
majority of MSI tumours cluster together and showed infrequent
copy number aberrations they were excluded for further analysis.
Supervised analysis of DNA associations with drug response. In
the univariate analysis of genome variation associated with
response to drug therapy, using the log-rank test, in total 92 and
94 patients receiving CAP and CAPIRI, respectively, and 119
patients receiving CAPOX-B were included (Fig. 1). Out of the
855 variant chromosomal subregions identiﬁed in the data pre-
processing step, 194 were signiﬁcantly associated with PFS in at
least one of the three treatment regimens at a P-valueo0.05. On
average these subregions covered 3.24Mb (0.004–23.84Mb,
s.d.¼ 4.28Mb) (Figs 3 and 4), and in total contain 3,979 mes-
senger RNA (mRNA) coding genes and 144 micro RNAs.
Twenty-four out of the 855 aberrant subregions, contained 744
genes and were associated to PFS with an uncorrected single-test
P-value ofo0.005, shown in Supplementary Table 2. In the CRC
The Cancer Genome Atlas (TCGA) data set with paired DNA
copy number and mRNA expression data, for 171 of the 744
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genes a positive correlation between DNA copy number and
mRNA expression level was found (Fig. 4, Supplementary
Table 2). Thirty-two out of these 171 genes were found to be
mutated in the data set from the ‘The genomic landscapes of
human breast and CRCs’ paper12 (Supplementary Table 2) and
141 were found to carry mutations in the TCGA data set. In
addition, 7 subregions, containing 103 genes, were associated to
PFS with an uncorrected single-test P-value ofo0.05 in at least 2
treatment regimens, shown in Supplementary Table 3. In the
TCGA data set, for 43 of these genes a positive correlation
between DNA copy number and mRNA expression level was
found (Figs 3 and 4, Supplementary Table 3). Five out of these 43
genes were mutated in the data set of ‘The genomic landscapes of
human breast and CRCs’ paper12 (Supplementary Table 3) and
35 of these genes were mutated in the TCGA data set.
DNA associations with CAP therapy. For patients treated with
CAP as a ﬁrst-line treatment one locus stood out, related to loss
of 5q. This locus (5q11.2–q13.2) concerns seven signiﬁcant
consecutive subregions of 13.5Mb in total with a signiﬁcantly
shorter PFS (Supplementary Table 2). The most signiﬁcant of
the seven sub-regions (5q12.1–q12.3) was lost in 20 patients for
which association reached a P-value of o0.001 (median 106
days versus 210 days for loss versus no loss, respectively,
Supplementary Fig. 4a). This subregion contains ﬁve genes
(SFRS12IP1, SDCCAG10, CENPK, PPWD1 and SFRS12) that
showed a signiﬁcant correlation between DNA copy number and
mRNA expression in the TCGA data set (Supplementary
Table 2). Among patients receiving CAPIRI and CAPOX-B,
no association of loss of this 5q region with PFS was seen
(Supplementary Fig. 4b and Supplementary Fig. 4c), while the
prevalence of this event was similar in all three treatment
groups.
DNA associations with CAPIRI therapy. For patients
treated with CAPIRI two loci stood out, related to gain of 6q and
Material
available
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CAIRO and CAIRO2
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820 patients of whom 633
underwent resection 
311 patients received
capecitabine1st-line (CAP)
CAIRO2
755 patients of whom
559 underwent resection 
322 patients received capecitabine
and irinotecan 1st-line (CAPIRI)
282 patients received
capecitabine, oxaliplatin and
bevacizumab(CAPOX-B)  
Of 191 patients tumour and
normal DNA available 
Of 221 patients tumour and
normal DNA available
188 tumour samples with
tumour cell %  70 
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which 11 passed DNA quality test
112 samples were hybridized
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tumour cell %  70
115 patients were selected
based on clinical variables
94 passed DNA quality test
21 new samples were selected of
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Figure 1 | Patient selection and data generation ﬂowchart. The ﬁnal data set of DNA copy number proﬁles based on several selection criteria, including
clinical variables, DNA quality and quality of the resulting copy number proﬁles.
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loss of 18q. The locus on chromosome 6 (6q16.1–q21) concerns
two signiﬁcant consecutive subregions of 14.5Mb in total with a
signiﬁcantly shorter PFS (Supplementary Table 2). The most
signiﬁcant of the two subregions (6q16.1–q16.3) was gained in 7
patients for which association reached a P-value of 0.002
(median 189 days for gain versus 262 days for no gain, Fig. 5b).
The total 14.5Mb region contains 15 genes (KIAA0776, C6orf66,
C6orf167, FBXL4, SFRS18, CCNC, ASCC3, ATG5, QRSL1,
6orf203, PDSS2, LACE1, CD164, SMPD2 and ZBTB24) that
showed a signiﬁcant correlation between DNA copy number and
mRNA expression in the TCGA data set.
The locus on chromosome 18q (18q21.1–q22.3) concerns ﬁve
signiﬁcant consecutive subregions of 24.5Mb in total with a
signiﬁcantly longer PFS. The most signiﬁcant of the 5 subregions
(18q21.33–q22.3) was lost in 78 patients which association
reached a P-value of 0.001 (median 270 days for loss versus 181
days for no loss, Supplementary Fig. 5b). The total 24.5Mb
region contains 37 genes (MYO5B, MBD1, CXXC1, C18orf24,
ME2, ELAC1, SMAD4, MEX3C, MBD2, POLI, RAB27B,
CCDC68, TXNL1, WDR7, FECH, NARS, ATP8B1, ALPK2,
MALT1, SEC11C, LMAN1, PMAIP1, RNF152, PIGN, KIAA1468,
TNFRSF11A, ZCCHC2, PHLPP, BCL2, KDSR, VPS4B, SER-
PINB8, TMX3, RTTN, SOCS6, C18orf55 and CNDP2) that
showed a signiﬁcant correlation between DNA copy number and
mRNA expression in the TCGA data set. Among patients
receiving CAP and CAPOX-B no association of gain of the 6q
and loss of the 18q region with PFS was seen (Fig. 5a,c,
Supplementary Fig. 5a and Supplementary Fig. 5c), while the
prevalence of these events was similar in all three treatment
groups.
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Figure 2 | Frequency plots of DNA copy number aberrations for the three mCRC patient groups. Panels from top to bottom CAP, n¼ 105 patient
samples; CAPIRI, n¼ 111 patient samples; CAPOX-B, n¼ 133 patient samples. Percentages of DNA copy number aberrations are based on called data.
x-axis, clones spotted on the array sorted by chromosomal position; vertical-dotted lines, boundaries between chromosomes. y-axis, percentage of
tumours with gains (positive values) or losses (negative values).
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Figure 3 | Genome-wide association of PFS with either gain or loss. x-axis, clones spotted on the array sorted by chromosomal position; vertical-dotted
lines, boundaries between chromosomes. y-axis, P-values of gains (positive values) or losses (negative values); horizontal-dotted lines show the threshold
of signiﬁcance (log-rank test using 10.000 permutations, n¼ 92, n¼94 and n¼ 119 in the patient groups receiving CAP, CAPIRI and CAPOX-B respectively,
single-test P-value o0.005) and the seven chromosomal bands that cross these lines are noted. The patient group receiving CAP is depicted in blue,
CAPIRI in red and CAPOX-B in green.
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DNA associations with CAPOX-B therapy. For patients treated
with CAPOX-B three loci stood out, related to loss of 5q, 17q and
18q. The locus on chromosome 5q (5q31.1–q35.4) concerns six
signiﬁcant consecutive subregions of 38.3Mb in total with a
signiﬁcantly shorter PFS (Supplementary Table 2). The most
signiﬁcant of the seven subregions (5q34) was lost in 15 patients
for which association reached a P-value of o0.001 (median 196
days for loss versus 390 days for no loss, Supplementary Fig. 6c,
Supplementary Table 2). This 66 Kb sub-region contains only one
gene (CCNG1) that showed a signiﬁcant correlation between
DNA copy number and mRNA expression in the TCGA data set.
The total 38.3Mb region contains 58 genes in total (CCNG1,
BRD8, KIF20A, DC23, ETF1, HSPA9, CTNNA1, SIL1, UBE2D2,
C5orf32, PFDN1, ANKHD1, SLC35A4, IK, WDR55, HARS,
HARS2, DIAPH1, HDAC3, KIAA0141, RNF14, NDFIP1, LARS,
RBM27, TCERG1, PCYOX1L, CSNK1A1, MED7, THG1L,
CLINT1, RNF145, UBLCP1, TTC1, SLU7,PTTG1, RARS,
CCDC99, NPM1, ERGIC1, C5orf25, HSPC111, HIGD2A, FAF2,
GPRIN1, UIMC1, LMAN2, GRK6, DDX41, RMND5B,
HNRNPAB, CLK4, ZNF354A, ZNF354B, RUFY1, CANX,
MAML1, MAPK9 and CNOT6) that showed a signiﬁcant corre-
lation between DNA copy number and mRNA expression in the
TCGA data set.
The locus on 17q (17q12–q21-31) concerns three consecutive
subregions of 6.0Mb in total with a signiﬁcantly shorter PFS
(Supplementary Table 2). The most signiﬁcant of the three
subregions (17q21-q21.31) was lost in 16 patients for which
association reached a P-value of 0.004 (median 278 for loss versus
389 days for no loss, Supplementary Fig. 7c). The total 6.0Mb
region contains 43 genes (PSMB3, PIP4K2B, CCDC49, RPL23,
LASP1, RPL19, FBXL20, MED1, CRKRS, NEUROD2, STARD3,
TOP2A, SMARCE1, TMEM99, KRTAP3-3, KRTAP1-1, EIF1,
NT5C3L, KLHL11, ACLY, NKIRAS2, KAT2A, COASY, MLX,
EZH1, VPS25, CCDC56, BECN1, PSME3, RUNDC1, RPL27,
BRCA1, NBR2, NBR1, DUSP3, TMEM101, LSM12, TMUB2,
GPATCH8, CCDC43, EFTUD2, NMT1 and MAP3K14) that
showed a signiﬁcant correlation between DNA copy number and
mRNA expression in the TCGA data set.
The locus on 18q (18q11.2) concerns only one subregion of
72 kb with a signiﬁcantly longer PFS (median 390 days for loss
versus 256 days for no loss, Supplementary Fig. 7f) and was lost in
78 patients for which association reached a P-value of 0.004.
However this region does not contain any genes that showed a
signiﬁcant correlation between DNA copy number and mRNA
expression in the TCGA data set. However three microRNAs are
located in this region (hsa-mir-320c-1, hsa-mir-133a-1 and
hsa-mir-1-2). Among patients receiving CAP and CAPIRI, no
association of loss of these regions with PFS was seen
(Supplementary Figs 6a,b and 7ab,d,e), while the prevalence of
this event was similar in all three treatment groups.
DNA associations with either CAP or CAPIRI therapy. For
patients treated with either CAP or CAPIRI as ﬁrst-line treatment
two loci stood out, related to loss (CAP) or gain (CAPIRI) of
either 5p14.3-p13.3 or Xp22.33 (Supplementary Table 3). The
locus on chromosome 5 concerns one region of 15Mb, loss of
which (n¼ 9) was associated with a signiﬁcantly shorter PFS for
CAP (median 106 for loss versus 199 days for no loss). However a
gain of this region on chromosome 5 (n¼ 23) was associated with
a signiﬁcantly shorter PFS for CAPIRI (median 241 for gain
versus 262 days for no gain), suggesting an opposite effect for
these two treatments. This region contains seven genes (RNASEN,
C5orf22, GOLPH3, MTMR12, ZFR, SUB1 and TARS) that showed
a signiﬁcant correlation between DNA copy number and mRNA
expression in the TCGA data set.
Whole genome 844 regions
CAPIRI 
mRNA~DNA
4 regions 
18 genes 
mRNA~DNA 
1 region 
7 genes 
mRNA~DNA
4 regions
36 genes
mRNA~DNA
7 regions
52 genes
mRNA~DNA
9 regions
101 genes
P-value < 0.005
7 regions
141 genes
P-value < 0.005
7 regions
51 genes
P-value < 0.005
10 regions
552 genes
P-value0.05 
72 regions 
1,247 genes 
P-value 0.05
57 regions
1,121genes
P-value ≤ 0.05
65 regions
1,718 genes
CAP 
CAPOX-B
Overlap CAPIRI & CAPOX-B
5 regions
75 genes
Overlap CAP & CAPIRI
2 regions
28 genes
Figure 4 | Venn diagram of chromosomal subregions. Chromosomal subregions show signiﬁcantly different PFS (log-rank test using 10.000
permutations, P-valueo0.05) for loss versus no loss or gain versus no gain found by supervised analysis. CAP in blue, CAPIRI in red and CAPOX-B in
green. Subregions with P-valueo0.005 and the number of genes located on those regions are shown, as well as the number of genes with correlating DNA
copy number and mRNA expression in the TCGA data set.
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The locus on chromosome X concerns one region of 669Kb,
loss of which (n¼ 8) was associated with a signiﬁcantly shorter
PFS for CAP (median 66 days versus 197 days for loss and no
loss, respectively) and a gain (n¼ 31) of which was associated
with a signiﬁcantly longer PFS for CAPIRI (median 335 days
versus 254 days for gain and no gain, respectively). This region
does not contain any gene that showed a signiﬁcant correlation
between DNA copy number and mRNA expression in the TCGA
data set. Furthermore no microRNAs were located in this region.
DNA associations with either CAPIRI or CAPOX-B therapy.
For patients treated with either CAPIRI or CAPOX-B two loci
stood out, related to loss of 18p11.32-21 and 18q11.2-12.1
(Supplementary Table 3). The locus on 18p11.32-21 concerns
three consecutive subregions of 14Mb in total, loss of which was
associated with a signiﬁcantly longer PFS for both treatment
regimens. This locus contains 35 genes (USP14, THOC1,
C18orf56, TYMS, ENOSF1, YES1, METTL4, NDC80, SMCHD1,
EMILIN2, LPIN2, MRCL3, MRLC2, ZFP161, RAB12, KIAA0802,
NDUFV2, ANKRD12, TWSG1, RALBP1, PPP4R1, VAPA, NAPG,
CHMP1B, MPPE1, IMPA2, TUBB6, AFG3L2, CEP76, PSMG2,
PTPN2, SEH1L, CEP192, C18orf19 and RNMT) that showed a
signiﬁcant correlation between DNA copy number and mRNA
expression in the TCGA data set. Interestingly, one of the genes
in this locus is TYMS, encoding for the target of capecitabine,
thymidylate synthase. However, no signiﬁcant correlation was
found of TYMS copy number status and PFS for treatment with
CAP. The locus on 18q11.2-12.1 concerns two consecutive sub-
regions of 2Mb in total, loss of which was associated with a
signiﬁcantly longer PFS for both CAPIRI and CAPOX-B
(Supplementary Fig. 8b,c). This locus contains one gene
(LAMA3) that showed a signiﬁcant correlation between DNA
copy number and mRNA expression in the TCGA data set.
Across regimen PFS. Associations of PFS across all 305 samples
obtained from the three patient groups, CAP, CAPIRI and
CAPOX-B, were made and have a prognostic rather than pre-
dictive value. An association of PFS with copy number status
yielded six chromosomal subregions with a log-rank P-
valueo0.005 (Supplementary Table 4), four of which are located
on chromosome 5 and overlap with the subregions found for one
arm (Supplementary Table 2). For the other two subregions, loss
of 104 kb at 1p31.1 and gain of 3630 kb at chromosome 9q12–
q13, signiﬁcance values of P-value 0.005 and 0.004 were observed,
whereas no signiﬁcance was reached within the independent
patient groups (Supplementary Fig. 9, shows Kaplan–Meier
curves for chromosome 9).
Between regimen PFS. As outlined above in the sub-section ‘ﬁnal
data set and descriptives’, overall PFS increased for patients
treated from CAP to CAPIRI to CAPOX-B. Interestingly, for
certain tumour genotypes this situation was different. For patient
samples with a loss of 5q12.1–q12.3, the PFS metrics for CAPIRI
and CAPOX-B were similar and superior to CAP (Supplementary
Fig. 4d), implicating that in this speciﬁc subgroup CAPIRI might
be a better ﬁrst-line treatment option compared with CAPOX-B
since former therapy is both less toxic and less expensive. For
patients without a loss of 5q12.1–q12.3, PFS with CAPOX-B was
signiﬁcantly better compared with the other two regimens
(Supplementary Fig. 4e), hence CAPOX-B might be a better
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Figure 5 | Kaplan–Meier PFS analysis for chromosomal subregion 6q16.1–q16.3. Within patients groups (a) CAP; (b) CAPIRI; (c) CAPOX-B, with gain in
green without gain in black. Between patient groups (d) gain of 6q16.1–q16.3; (e) no gain of 6q16.1–q16.3, with CAP in blue, CAPIRI in red and CAPOX-B in
green. Log-rank P-values, Po0.005 are considered signiﬁcant; pval1, CAP versus CAPIRI; pval2, CAP versus CAPOX-B; pval3, CAPIRI versus CAPOX-B; n,
number of patients; median, median survival with conﬁdence limits within brackets and NA, not applicable.
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treatment option for this subgroup of patients. For patients with a
loss of 18q21.33–q22.3, the PFS metrics for CAPIRI was superior
to CAP, but without a loss of 18q21.33–q22.3 the PFS metrics
were similar. Also for patient samples with a gain of chromoso-
mal subregion 6q16.1–q16.3 PFS metrics were similar for CAPIRI
and CAP (Fig. 5d). These examples indicate that adding irino-
tecan to capecitabine does not have an effect on response in
patient groups with either a gain of 6q16.1–q16.3 or without a
loss of 18q21.33–q22.3, unlike the subgroup of patients without a
gain of 6q16.1–q16.3 or with a loss of 18q21.33–q22.3. Finally, for
patients with a loss of subregion 5q34 the PFS was signiﬁcantly
better when treated with CAPIRI, compared with the other two
regimens (Supplementary Figs 6d,e).
In vitro validation of DNA associations with drug response. To
evaluate whether, also in vitro, presence or absence of the chro-
mosomal regions identiﬁed were associated with drug sensitivity,
copy number aberrations for cell lines in the Catalogue of Somatic
Mutations in Cancer (COSMIC)21 were matched with the drug
response data (IC50 values) from the Genomics of Drug
Sensitivity in Cancer project (GDSC)22. Of the four different
drugs used in the CAIRO or CAIRO2 clinical trials, response data
was available for SN-38, which is the active metabolite of
irinotecan, but not for any of the other three drugs used in these
regimens. In the between regimen analysis, three (concatenated)
chromosomal regions, 6q16.1 q21 gain, 5q11.2 q13.2 loss and
18q21.1 q22.3 loss, associated with a signiﬁcant difference in
PFS between patients treated with irinotecan plus capecitabine
and those treated with capecitabine alone (Supplementary
Table 2). For the 573 COSMIC cell lines with available GDSC
drug response data, a signiﬁcant association between
chromosome 6q16.1 q21 gain and viability under SN-38
treatment was observed (n¼ 350 gain, versus n¼ 223 no gain,
P¼ 0.01). Similarly, for the subset of 31 CRC cell lines alone a
signiﬁcant association for gain of 6q16.1 q21 with SN-38
treatment was observed (n¼ 31, 14 gain versus 17 no gain,
P¼ 0.05) (Supplementary Fig. 10a and Fig. 6). P-values did not
reach signiﬁcance for either of the other two chromosomal
regions that associated with a signiﬁcant difference in PFS in the
patient samples (Supplementary Table 5, Supplementary
Figs 10b,c and 11).
Genes and drug targets in chromosomal ampliﬁcations.
Ampliﬁcations in cancer are of special interest as these may
contain driver oncogenes. Across the present series of 349 pri-
mary CRC tissue samples, in total 432 ampliﬁcations were
detected. An overview of the top 25 most frequent ampliﬁcations
identiﬁed, along with the genes located at these loci, is presented
in Table 1. Forty-three out of these 80 genes have previously been
associated with cancer in general and/or with CRC in parti-
cular11,12,15. In addition ampliﬁcations of the genes VEGFA and
EGFR were found in, respectively, 2 and 1 samples from the 349
patients. One of the most appealing aspects of ampliﬁcations is
their possible association to drug therapy, with trastuzumab
sensitivity in ERBB2(Her2neu) ampliﬁed breast cancer as a classic
example. Therefore, gene targets of both Food and Drug
Administration (FDA)-approved drugs as well as drugs under
(pre-) clinical evaluation were mapped to the genes in the
ampliﬁcations identiﬁed (Table 2). Moreover, the list of ampliﬁed
genes also contained kinases, ligands and receptors that have not
yet been targeted (n¼ 25; Supplementary Tables 6–8). Examples
of DNA copy number proﬁles with ampliﬁed regions containing
genes including drug targets are shown in Fig. 7. Among the
signal transduction pathways, the RAS, RAF and ERK pathway23
is of particular interest in mCRC, given the role of anti-EGFR
therapy in these patients. Seventeen genes in this pathway,
ranging from ligands to downstream targets, were found to be
ampliﬁed, of which AKT5 and MYC occurred in ﬁve of the
patients. Ampliﬁcation of KRAS occurred in two patients and
ERBB2 in three patients (Supplementary Table 9).
Discussion
The diversity of the genomic landscape in CRC overall has
been12,13,15 and still is under active investigation, for example, in
the context of TCGA and the International Cancer Genome
Consortium (ICGC)24. These efforts have painted a canvas of the
genomic diversity in CRC, ranging from the ‘Vogelgram’ model
of somatic mutations in the pathogenesis of CRC to the
‘mountains and hills’ concept2,12. Next to that, also evident
patterns of DNA copy number aberrations as well as DNA
methylation changes have been documented25,26. The challenge is
to associate this genomic diversity to phenotypic characteristics,
such as response to systemic treatment. The ﬁeld of somatic
genomic variation, with neoplasia as main associated phenotype,
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is substantially lagging behind that of germ-line genomic
variation, that is, clinical genetics and molecular epidemiology.
An important lesson from this latter ﬁeld teaches us that
homogeneity of phenotype is a key factor in genome-wide
association studies. This is eminent from the fact that many
important genomic associations actually have been discovered in
inbred populations. This puts high demands on the quality and
level of detail of phenotypic annotation, to such an extent that so
far in a multicentre setting this almost only has been feasible in
prospective studies like phase III clinical trials, examples of which
are PETACC-3 (ref. 16) and the present study. Similar demands
go for the samples studied and the genomic read-out systems
used. As to the latter, the aim is to capture as much as possible of
the spectrum genomic aberrations in the tumour samples, under
the restrictions imposed by sample types available. For many
tumour types this limits methods to those that can be applied to
the FFPE archival material harvested from the resection
specimen. In practice, this restricts the read out to the DNA
level, and aCGH still is a widely validated technology for
capturing genome-wide variation from FFPE samples20,27. The
existence of an operational national pathology archive further
facilitated the retrieval and processing of the resection samples of
the current study under thorough quality control28. Patients
studied had participated in either of the two Dutch multicentre
mCRC phase III clinical trials, that is, CAIRO (ref. 17) and
CAIRO2 (ref. 18), and FFPE tissues were analyzed for
associations between somatic genomic variation and clinical
phenotype, that is, between high-resolution genome-wide DNA
copy number aberrations and PFS to ﬁrst-line palliative systemic
therapy. This study yielded many promising associations between
DNA copy number aberrations and response to ﬁrst-line drug
therapy within and between treatment arms. Three chromosomal
regions showed statistically promising associations for patients
treated with or without irinotecan. Irinotecan sensitivity could be
validated through association with DNA copy number
aberrations of cell lines from the COSMIC21. Consistent with
the observations we made with the clinical samples, a signiﬁcant
association with viability for all cell lines, as well as for the CRC
cell lines alone was observed for one of the three chromosomal
regions of interest, namely gain of 6q16.1 q21. Other ﬁndings
reported here still await external validation, and at this point in
time those results should be considered hypothesis generating.
Yet, the release of this large body of high-quality data, both in
terms of phenotype annotations and genomic read out, to the
wider scientiﬁc community will provide the best chance of such
validation.
In addition to studying the associations of genome-wide DNA
copy number aberrations to PFS for three different drug regimens
in mCRC, we also documented the prevalence of ampliﬁcations in
mCRC. These ampliﬁcations, that apparently are associated with
a selection advantage for the prevailing tumour clone in the
individual patient, may give rise to overexpression of oncopro-
teins that are targets of currently available drugs. The classical
example of this is ampliﬁcation of Her2neu (ERBB2) in breast
cancer, but that also was present in three of the CRC samples
studied. Genes in ampliﬁed regions included several known
targets for FDA-approved drugs and potential targets of
therapeutic interest were identiﬁed. We hypothesize that
ampliﬁcation of drug targets in these tumours may be of help
for treatment selection in individual patients. FGFR1, a known
target receptor of pazopanib and regorafenib, showed high-level
gains in 3.7% of patients in the present study and might represent
Table 1 | Overview of top 25 most frequent ampliﬁcations identiﬁed by high-resolution aCGH in 349 primary tumour samples of
colorectal cancer patients that ultimately developed distant metastases.
Chr Band Start (kb) End (kb) Frequency Genes at the locus of ampliﬁcation
8 8p23.1 7729.31 7747.83 6 SPAG11A
8 8p12 38056.98 38195.55 4 ASH2L STAR LSM1 BAG4
8 8p12 38295.33 38410.39 7 LETM2 FGFR1*
8 8p11.23 39356.6 39402.49 5
8 8p11.23 39464.58 39482.04 6
8 8p11.21 41468 41567.59 5 GOLGA7 GINS4 AGPAT6
8 8q24.21 128387.5 129035.7 5 DQ515898 DQ515899 DQ515897 POU5F1*, MYC* PVT1 TMEM75
11 11q14.3 89402.45 89457.56 4 TRIM49
12 12p13.31 9554.15 9582.76 15
13 13q12.13 26419.12 26496.5 4
13 13q12.2 27366.6 27711.8 5 PDX1 CDX2*, PRHOXNB FLT3* PAN3
13 13q21.31 63231 63293.05 4
13 13q22.1 72712.75 72880.71 6
18 18q21.1 44805.82 44837.45 4
18 18q21.1 45094.24 45159.05 4
19 19q13.2 44256.77 45231.21 5 PAK4 NCCRP1 SYCN IL28B IL28A IL29 LRFN1 GMFG SAMD4B PAF1
MED29 CR601007 ZFP36 PLEKHG2 RPS16 SUPT5H TIMM50 DLL3 EID2B
EID2 LGALS13 AK023628 LGALS14 CLC DYRK1B FBL FCGBP PSMC4 ZNF546
19 19q13.2 45355.25 45544.88 5 MAP3K10 TTC9B CNTD2 AKT2* C19orf47
20 20q13.11–q13.12 41179.95 41732.85 4 SFRS6w L3MBTL SGK2 IFT52 MYBL2
20 20q13.12 42494.6 42562.9 4 C20orf62 TTPAL SERINC3
20 20q13.32 56021.92 56663.86 5 C20orf85 PPP4R1L RAB22A VAPB APCDD1L AK091704 AK054637 STX16
20 20q13.33 61334.28 61398.13 5 BIRC7 NKAIN4 ARFGAP1 COL20A1
20 20q13.33 62202.02 62351.03 6 OPRL1 NPBWR2w MYT1
23 Xq21.31 88529.93 88545.42 4
23 Xq21.31 88563.15 88563.21 4
23 Xq21.31 89760.38 89824.39 4
aCGH, array comparative genomic hybridization; Chr, chromosome.
*Cancer census genes11.
wMutated in data from the ‘The genomic landscapes of human breast and colorectal cancers’12.
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an appealing example, since a recent report indicated that
treatment with regorafenib results in a modest PFS and overall
survival beneﬁt in unselected patients with refractory mCRC
compared with placebo29.
In the present study, chromosomal copy number aberrations
from primary tumours rather than from the actual metastases
were analyzed, even though the goal was to associate disease
biology to response to drug therapy for metastatic disease. One
may argue that the clones that have metastasized would differ
substantially from the primary tumour. While such changes do
occur, and secondary mutations may contribute to drug
resistance, like in gastrointestinal stromal tumour and non-small
cell lung cancer, primary tumours and their metastases share the
vast majority of genetic aberrations, which of course is not
surprising for an evolutionary process. We recently demonstrated
that DNA copy number aberrations mostly persist in CRC
metastases30, which is consistent with KRAS mutation status in
primary and mCRC31. Differences between tumours from
different patients are greater than between primary tumours
and their metastases30, which is consistent with the
predestination hypothesis that poses the full genomic
programme that determines if the biological and clinical
phenotype of a tumour is already present at the time when a
primary cancer arises32. Whether patients with liver metastases
will beneﬁt from a given drug therapy will largely depend on the
biological characteristics of their disease. Given the high level of
conservation of genomic characteristics of the primary tumour in
the associated metastasis, answer to this clinically relevant
question indeed may come from analysis of the primary
tumour tissue, as also has been well-demonstrated for KRAS
mutation analysis in case of anti-EGFR therapy3.
Inherent to the search for biological subgroups of any type of
cancer that may differ in their response to drug therapy is the fact
that such subgroups may represent rather small proportions of
the overall disease phenotype. This poses a challenge to the
statistical strategies we use to exclude the risk of scientiﬁc
observations being merely due to chance. Statistical methods
available to estimate the probability of these so called type I errors
have their optimal performance when variant subsets are of equal
and sufﬁcient size, and consequently may overestimate the
probability of associations involving small subgroups being due to
chance. Evaluation of descriptive data like Kaplan–Meier curves,
however, showed several instances of infrequent aberrations with
relatively strong associations. This is an indication that genomic
diversity in CRC is greater than anticipated, and that these small
genomic hills still may be highly relevant in a clinical setting.
Therefore an urgent need exists to design and organize studies for
validating such observations in a way in which they can provide
solid ground for clinical decision making.
Methods
Sample selection. Patients selected for the current study participated in either of
the two multicentre phase III trials of the Dutch Colorectal Cancer Group (DCCG),
namely CAIRO (CKTO 2002-07, ClinicalTrials.gov; NCT00312000) and CAIRO2
Table 2 | Drug target genes at ampliﬁcations in 349 primary tumour samples of patients that ultimately developed distant
metastases.
GeneID Chr Frequency Drug Drug class
Clinically available targeted anticancer agent-related genes
FGFR1 8 8 Pazopanib TKI
FLT3 13 5 Sorafenib, sunitinib TKI
FLT1 13 4 Sunitinib, pazopanib, axitinib TKI
HSP90AB1 6 2 17-DMAG, IPI-504 (retaspimycin) HSP90 inhibitor
VEGFA 6 2 Bevacizumab, ranibizumab, aﬂibercept, pegaptanib Anti-vegf MAb; vegf receptor decoy; anti-vegf aptamer
CDK8 13 1 Flavopiridol Anti-cdk ﬂavonoid
Cytotoxic drug-related genes
ADA 20 3 Pentostatin, vidarabine Antimetabolite
TUBB1 20 2 Docetaxel, epothilone B; vinorelbine Taxane; vinca-alkaloid
Target genes of drugs for other indications
DGAT1 8 3 Omacor Antilipemic
HRH3 20 3 Tesmilifene, triprolidine, buclizine Antihistamine/anticholinergic
FNTA 8 2 Lonafarnib, tipifarnib Farnsesyl transferase inhibitor
CD40 20 1 SGN-40 (dacetuzumab) Anti-hucd40 MAb
TNFSF13B 13 1 Belimumab BLyS-speciﬁc inhibitor
Target genes for drugs without apparent anticancer activity
OPRL1 20 6 ZP120
CHRNA4 20 4 Pancuronium
OGFR 20 3 Enkephalin, methionine
NTSR1 20 3 Contulakin-G
COL9A3 20 3 Collagenase clostridium histolyticum
CHRNB3 8 2 Pancuronium
CHRNA6 8 2 Pancuronium
F10 13 1 Dalteparin, heparin, enoxaparin
COL4A2 13 1 Collagenase clostridium histolyticum
F7 13 1 Nematode anticoagulant protein c2
PDE7A 8 1 Anagrelide, tolbutamide, theophylline
AHCY 20 1 3-deazaneplanocin, neplanocin A
COL4A1 13 1 Collagenase clostridium histolyticum
Chr, chromosome; MAb, monoclonal antibody; TKI, tyrosine-kinase inhibitor.
Genes are ordered as targets of targeted anticancer agents, cytotoxic drugs, drugs approved for indications other than cancer and drugs without known anticancer effects.
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(CKTO 2005-02, ClinicalTrials.gov; NCT00208546). The two randomized clinical
trials were approved by the Committee on Human-Related Research Arnhem—
Nijmegen and by the local institutional review boards. The written informed
consent required for all patients before study entry also included translational
research on tumour tissue. In the CAIRO study, 820 patients with mCRC without
prior palliative systemic treatment were randomized between sequential (arm-A,
ﬁrst-line CAP, second-line irinotecan and third-line CAPOX) and combination
treatment (arm-B, ﬁrst-line CAPIRI and second-line CAPOX)17. In the CAIRO2
study, 755 patients were randomly assigned to ﬁrst-line treatment with
capecitabine, oxaliplatin and bevacizumab (arm-A, CAPOX-B), or the same
regimen combined with cetuximab (arm-B)18. From CAIRO2, only samples from
patients in arm-A were included, since a worse PFS for patients in arm-B was
observed, which may have been caused by a negative interaction between
bevacizumab and cetuximab. In the present study we included patients in whom
FFPE tissue of the primary tumour as well as matched normal DNA for reference
purposes was available through the national pathology registry PALGA28.
Inherently these are the patients who underwent resection of the primary tumour,
of whom 311, 322 and 282 patients were included from the CAP, CAPIRI and
CAPOX-B treatment groups, respectively. Of these, tissue samples were available
for 221 patients receiving CAP, 257 patients receiving CAPIRI and 191 patients
receiving CAPOX-B.
Stringent criteria were used to select patients based on tumour cell percentage of
the tissue sample, clinical variables, DNA quality and quality of the resulting copy
number proﬁles (Fig. 1). Haematoxylin and eosin-stained tissue sections were
reviewed by a pathologist to determine the percentage of tumour cells. Only
tumours containing an area of at least 70% tumour cells were selected for DNA
extraction. After exclusion of samples with insufﬁcient tumour cell content, 188,
178 and 158 samples from the CAP, CAPIRI and CAPOX-B patient groups,
respectively, were available for further analysis. From these, 109 samples were
selected from the CAP, 115 from the CAPIRI and 141 from the CAPOX-B
treatment group. The patient samples were matched according to the stratiﬁcation
factors in the original studies (for the subgroup of patients that underwent
resection of the primary, since these are the patients from whom material was
available to be included in this study), that is, performance status, predominant
metastatic site, previous adjuvant therapy and serum lactate dehydrogenase level
(LDH) in CAIRO (CAP and CAPIRI) and number of affected organs, previous
adjuvant therapy and serum LDH in CAIRO2 (CAPOX-B).
DNA isolation, labelling and quality assessment. For the selected samples,
tumour and matched normal reference DNA was isolated from FFPE tissue blocks
as described previously20. Haematoxylin and eosin sections of 3–5 mm thickness
were cut prior to the sections used for DNA isolation33. Four to six 10 mm adjacent
sections were cut, de-parafﬁnized, and macro dissected. DNA was extracted using a
column-based method (QIAamp microkit; Qiagen, Hilden, Germany)34. Labelling
was performed using the Enzo Genomic DNA Labeling kit according to the
manufacturer’s instructions (Enzo Life Science, Farmingdale, NY, USA)35 and
puriﬁed using the QIAGEN MinElute PCR Puriﬁcation Kit with an elution volume
of 2 10.5 ml. (Qiagen, Westburg, Leusden, Netherlands). Quality of labelled DNA
was tested with the NanoDrop 1,000 (Thermo Fisher Scientiﬁc, Delaware, USA) by
measuring the speciﬁc activity (pico mole dye per microgram genomic DNA). If for
either tumour or normal reference a speciﬁc activity o16 pmol mg 1 was
measured, samples were considered insufﬁcient and were replaced by clinically
comparable samples. If both tumour and reference were between 12 and
16 pmol mg 1, but had equal speciﬁc activity, they were not excluded. This method
of DNA quality testing was extensively examined by hybridizing samples with
decreasing speciﬁc activity. The resulting DNA copy number proﬁles were
evaluated by visual inspection and the MAD value34. Tumour and matched normal
reference samples with a speciﬁc activity of at least 16 pmol mg 1 turned out to
result in good quality copy number proﬁles. In addition tumour and matched
normal reference samples with equal speciﬁc activity 412, but o16 pmol mg 1,
turned out to result in copy number proﬁles of sufﬁcient quality. Fourteen, 21 and
6 samples in the CAP, CAPIRI and CAPOX-B patient groups, respectively, did not
pass the DNA quality test and were replaced by other samples of which in the end
11, 19 and 0 samples passed the test.
Array hybridizations. In total, 112, 113 and 136 tumour and matched normal
reference samples were hybridized on the 4 180K customized Agilent oligonu-
cleotide arrays (Agilent Technologies, Palo Alto, CA, USA). These arrays contain
180,880 in situ synthesized 60-mer oligonucleotides, representing 169,793 unique
chromosomal locations distributed across the genome at B17 kb intervals and is
enriched with 4,548 additional unique oligonucleotides, located at 238 of the
Cancer Census genes11. The exact array design can be found in the Gene
Expression Omnibus (GEO)36 platform GPL8687 (http://www.ncbi. nlm.nih.gov/
geo). Labelling was performed using the Enzo Genomic DNA Labeling kit
according to the manufacturer’s instructions (Enzo Life Sciences, Raamsdonksveer,
Netherlands). Cy3- and Cy5-labelled DNA samples were combined with Cot-1
DNA (Invitrogen, Breda, Netherlands) and blocking agent in hybridization buffer
(Agilent Technologies). Hybridization mixture was heated for 3min at 95 C and
subsequently incubated for 30min at 37 C. Hybridization was performed for 24 h
at 65 C followed by 5min washing with wash buffer 1 at room temperature (RT),
and 1min with wash buffer 2 at 37 C and 1min with acetonitrile at RT35.
Microarray scanner G2505C (Agilent technologies) was used for scanning, and
feature extraction software (version 10.5.1.1; Agilent Technologies, protocol
CGH_105_Dec08) was applied using default settings. To keep all experiments
comparable, no quality ﬂagging was applied and all oligonucleotides were included
in the downstream analysis. The oligonucleotides were mapped along the genome
according to the NCBI36/hg18 built (March 2006). Of both Cy3 and Cy5 channels,
local background was subtracted from the median intensities. The log2 ratios were
calculated and normalized by subtraction of the median value of all probes spotted
on the array. Normality of the matched normal reference DNA was evaluated in
silico by comparison with a reference pool of normal FFPE DNA, using the across
array approach35. DNA copy number proﬁles with MAD values40.4 were excluded.
For technical reasons, for ﬁve samples, the matched normal reference was replaced by a
reference pool of normal FFPE DNA in silico, using the same across array approach35.
DNA copy number data pre-processing. Genome data analysis was performed in
the programming language R 2.9.1. The aCGH proﬁles were ﬁrst dewaved37 and
then the median was normalized. For segmentation, the Bioconductor R-package
DNAcopy version 1.22.1 (ref. 38) was applied followed by post segmentation mode
normalization. Proﬁles were corrected for tumour cell percentage, and DNA copy
number calls for loss, normal, gain or ampliﬁcation were made using the using
R-package CGHcall version 2.8.0 (ref. 39), applying posterior probabilities of 0.5 or
higher. Ampliﬁcations were furthermore deﬁned by a chromosomal size of 3Mb or
less according to Leary et al.13 Accuracy of normalization, segmentation and calling
was veriﬁed by visual inspection. To reduce dimensions of the aCGH data set
without losing information, the information of the 180.000 probes was reduced to
855 chromosomal subregions using the Bioconductor R-package CGHregions
version 1.6.0 (ref. 40) and contains all the genomic variation in this data set of 349.
For functional validation purposes, chromosomal subregions that signiﬁcantly
associated with PFS (uncorrected single-test P-valueso0.005) were concatenated to
a ‘total’ chromosomal region if they occurred within one chromosomal arm.
Downstream analysis and integration with clinical data. Regions of gains and
losses were used for supervised and unsupervised analysis. The R-package WECCA
version 0.30 (ref. 41), designed for clustering copy number proﬁles rather than
expression proﬁles, was used with probabilities as described by Smeets et al.42 with
settings: ‘ordinal’, ‘all equal’ and ‘Ward linkage’. For supervised analysis, only those
patients were included who received at least three treatment cycles or two cycles if
patients died due to (rapidly) progressive disease. In addition, microsatellite
instable samples, as determined previously43, were excluded since they showed
infrequent copy number aberrations. In total, 92, 94 and 119 patients treated with
CAP, CAPIRI and CAPOX-B, respectively were included. A log-rank test using
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Figure 7 | Representative examples of DNA copy number proﬁles with
ampliﬁed regions containing known drug targets. Four tumour DNA copy
number proﬁles with ampliﬁcations containing the genes (a) EGFR, (b)
FGF3, (c) VEGFA and (d) FGFR1, respectively. x-axis data points at probe
level plotted from chromosome 1 to 22 and x with boundaries of
chromosomes indicated by vertical-dotted lines. y-axis, log2 ratios.
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10.000 permutations was performed to calculate the signiﬁcance of DNA copy
number correlations to PFS of the ﬁrst-line treatment in each study arm44
(uncorrected single-test P-valueso0.005, corresponding to permutation-based
False Discovery Rates in the range 20–30%). Separate analyses were run on gains or
losses to test for associations with PFS.
Gene identiﬁcation. UCSC genes (hg18; ref. 45) were mapped to the genomic
regions that showed an association to PFS with a P-valueo0.05. For gene
identiﬁcation, the association of DNA copy number aberrations with mRNA
expression was evaluated using publicly available data from TCGA 8 July 2011
update15,46. This set consisted of 141 CRCs for which both DNA copy number data
(obtained with the Affymetrix SNP 6.0 platform) and mRNA expression data
(Agilent G4502A platform) were available. To further narrow down at the gene
level, only those genes were considered that were located on regions that showed an
association to PFS with a P-valueo0.005 in any arm, or with a P-valueo0.05
in at least two arms and that showed a positive correlation between DNA copy
number status and mRNA expression. To investigate genes with a possible role in
drug pathways, the Pharmacogenomics Knowledge Base23,47–50 (http://
www.pharmgkb.org/) was used. Furthermore, genes identiﬁed in our study were
overlaid with genes identiﬁed in other landscape papers, including ‘The genomic
landscapes of human breast and CRCs’ and the TCGA data set12,15.
Drug target genes were extracted from this list with Ingenuity Pathway Analysis
version 8.7 (IPA, http://www.ingenuity.com/) taking all drug target genes,
regardless of drug class, into account. Drug target genes that were located at
ampliﬁed chromosomal loci were ordered according to the indication and
mechanism of action of the drug associated with this speciﬁc gene. If multiple
drugs were listed by IPA for targeting a speciﬁc gene, a maximum of three drugs
were shown in the corresponding tables of this paper, giving priority to FDA-
approved drugs that are most frequently used and representative of the drug class
as well as agents furthest in (pre-) clinical development. Potential drug target genes
were also selected by searching for known receptors and ligands in the Database of
Interacting Proteins (http://dip.doe-mbi.ucla.edu/dip/). In addition, we have identiﬁed
genes coding for kinases by categorizing the original gene list in IPA version 8.7.
Drug sensitivity validation data and procedures. Chromosomal copy number
data from 1,005 cell lines were downloaded from the COSMIC21 on 25 April 2014
via the URL http://cancer.sanger.ac.uk/cancergenome/projects/cell_lines. These
data had been generated using Affymetrix SNP 6.0 arrays (1.8 million genetic
markers, GEO accession number: GPL6801; Affymetrix, Santa Clara, USA) and
processed using PICNIC51. Chromosomal regions of copy number42, gain, ¼ 2,
normal (diploid) and o2, loss, were inferred (mapped to NCBI37/hg19). The half
maximal inhibitory concentration (IC50) values for SN-38 (7-Ethyl-10-Hydroxy-
Camptothecin), the active metabolite of irinotecan were available for 578 cell of the
COSMIC lines and were downloaded via the Sanger Welcome Trust-GDSC project
portal http://www.cancerrxgene.org22 on 25 April 2014. No IC50 data were
available for 5 ﬂuorouracil/capecitabine, oxaliplatin or bevacizumab. Chromosomal
subregions for signiﬁcant associations with PFS were observed in the patient
samples (Supplementary Table 2), were concatenated if they were adjacent and
occurred within one chromosomal arm, thereby reducing the number of regions to
seven main chromosomal regions, three of which were signiﬁcantly correlated with
irinotecan treatment. Coordinates of these three regions were mapped to NCBI37/
hg19 using the liftOver tool at UCSC (http://hgdownload.cse.ucsc.edu/admin/exe).
Cell lines were classiﬁed for each of the three regions as aberrant (gain or loss) for
any overlap. A Kruskal–Wallis test was applied per region to assess if the
distribution of IC50 values for cell lines with a chromosomal aberration (gain or
loss) was signiﬁcantly different from those without a chromosomal aberration
(normal), for all cell lines (n¼ 573) and the CRC cell lines alone (n¼ 31). Only
three regions were tested, hence uncorrected P-valuesp0.05 were considered
statistically signiﬁcant.
Data analysis strategy. Discovery of DNA copy number aberrations associated
with PFS under the three drug regimens was performed on the aCGH data from
the CAIRO (CAP and CAPIRI) and CAIRO2 (CAPOX-B) samples. For biological
validation, the association of DNA copy number aberrations of the genes involved
with mRNA expression was evaluated using publicly available data from
TCGA15,46. This data set consisted of 141 CRCs for which both DNA copy number
data (obtained with the Affymetrix SNP 6.0 platform) and mRNA expression data
(obtained with the Agilent G4502A platform) were available.
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